Skip to main content

Knight Therapeutics Inc(GUD-T)
TSX

Today's Change
Real-Time Last Update
Day Low5.50
Day High5.66
Open:5.61
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
GlobeNewswire
Knight Therapeutics Announces Approval of Minjuvi® (tafasitamab) in Mexico
GlobeNewswire
Knight Therapeutics Inc. places No. 397 on The Globe and Mail's sixth annual ranking of Canada's Top Growing Companies
GlobeNewswire
Knight Therapeutics Reports Second Quarter 2024
GlobeNewswire
Notice of Knight Therapeutics' Second Quarter 2024 Results Conference Call
GlobeNewswire
Knight Announces Normal Course Issuer Bid
GlobeNewswire
Knight Therapeutics Reports First Quarter 2024 Results
GlobeNewswire
Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Ironshore Pharmaceuticals & Development, Inc. for JORNAY PM® for Canada and Latin America
GlobeNewswire
Knight Therapeutics Inc. announces voting results from the Annual General Meeting
GlobeNewswire
Knight to Present at the 2024 RBC Capital Markets Global Healthcare Conference in New York City
GlobeNewswire
Notice of Knight Therapeutics' First Quarter 2024 Results Conference Call
GlobeNewswire
Knight to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
GlobeNewswire
Knight Therapeutics Inc. ranks on The Globe and Mail’s fifth-annual Women Lead Here benchmark of executive gender diversity
GlobeNewswire
Knight Therapeutics Reports Fourth Quarter and Year-End 2023 Results
Baystreet
Stocks in play: Knight Therapeutics Inc.
GlobeNewswire
Notice of Knight Therapeutics' Fourth Quarter and Year End 2023 Results Conference Call
Baystreet
Stocks in play: Knight Therapeutics Inc.,
GlobeNewswire
Knight Therapeutics Announces Launch of Minjuvi® in Brazil
GlobeNewswire
Knight Therapeutics Inc. Celebrates its First Decade of Success
GlobeNewswire
Knight Therapeutics Announces Regulatory Submission of Fostamatinib in Brazil
GlobeNewswire
Knight Therapeutics Announces Launch of Bijuva® in Canada
GlobeNewswire
Knight Therapeutics Enters into Exclusive License Agreement with Amneal Pharmaceuticals for IPX203

Profile

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Latin America and select international markets . The company finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights. Geographically the company generates revenue from Brazil, Colombia, Argentina, Rest of LATAM, Canada, and Other, with the majority revenue generated from the Brazil region.